Reduction of hemolytic blood damage with dextran

  title={Reduction of hemolytic blood damage with dextran},
  author={Robert C. Lijana and MICHAEL C. Williams},
  journal={Aiche Journal},
3 Citations
Novel pullulan bioconjugate for selective breast cancer bone metastases treatment.
In vitro studies showed that Pull-(GGPNle-φ-PTX)-(PEG-ALN) had strong affinity for hydroxyapatite, which simulates the bone tissue, and the nanoconjugate inhibited the migration of cancer cells and further displayed potent anti-angiogenic activity.
A new mock circulatory loop and its application to the study of chemical additive and aortic pressure effects on hemolysis in the Penn State electric ventricular assist device.
A compilation of data gathered in these experiments showed that the index of hemolysis (IH) is dependent on hematocrit (HCT), which suggests that another parameter, IH/HCT, may be more suited to the quantification of Hemolysis.
Can blood additives reduce hemolysis in an artificial heart?
A 340 ml mock circulatory loop composed entirely of Biomer, stainless steel, and silicon was designed and assembled and it can be concluded that none of these additives can be used as hemolysis-reducing drugs in artificial heart patients.